Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Bristol-Myers

Executive Summary

Robert Nowinski, PhD, to VP-new technology. Science & Technology Group. He continues as a corporate VP and president of subsidiary Genetic Systems. Nowinski was a founder of Genetic Systems, acquired by Bristol in 1986; Marvin Gorman, PhD, to exec VP of biotech research subsidiary Oncogen; Charles Heimbold, president of B-M's Health Care (non-pharmaceutical) Group, will assume corporate responsibility for planning and development, succeeding John Melton, who has resigned.

Robert Nowinski, PhD, to VP-new technology. Science & Technology Group. He continues as a corporate VP and president of subsidiary Genetic Systems. Nowinski was a founder of Genetic Systems, acquired by Bristol in 1986; Marvin Gorman, PhD, to exec VP of biotech research subsidiary Oncogen; Charles Heimbold, president of B-M's Health Care (non-pharmaceutical) Group, will assume corporate responsibility for planning and development, succeeding John Melton, who has resigned.
Table

View full table

Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS013438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By